BFH772 (VEGFR2 inhibitor): Technical Protocols and Workflow Guide

What This Product Solves

BFH772 is a potent and highly selective VEGFR2 kinase inhibitor designed for laboratory research environments where targeted inhibition of VEGFR2-mediated angiogenesis is required. This compound specifically addresses the need for a research reagent that can modulate VEGFR2-driven signaling with minimal off-target kinase effects. Its selectivity—demonstrating an IC50 of 3 nM for VEGFR2 and significantly reduced potency for related kinases—makes it suitable for studies dissecting the VEGFR2 signaling pathway in tumor angiogenesis, without confounding results from broader kinase inhibition. Researchers working with tumor angiogenesis models or investigating the mechanistic roles of VEGFR2 in vascular development will find BFH772 appropriate for in vitro and in vivo workflows where water solubility is not a requirement.

For further context on BFH772's niche application, the article "BFH772 (VEGFR2 inhibitor): Technical Guide for Angiogenesis Research" reviews its selectivity and its incompatibility with broad-spectrum protocols. Additionally, "BFH772 (VEGFR2 inhibitor): Technical Use and Workflow Guidance" details its suitability for workflows where organic solvent compatibility and precise kinase targeting are critical.

Protocol Parameters

• Assay: VEGFR2 kinase inhibition
  Value: IC50 = 3 nM
  Applicability: Use for in vitro kinase assays or cell-based models targeting VEGFR2 signaling.
  Rationale: Ensures potent and highly selective inhibition of VEGFR2, minimizing off-target activity in experimental systems.
  Source Type: Product dossier (BFH772 (VEGFR2 inhibitor))
• Assay: Solubility in DMSO
  Value: ≥53.4 mg/mL
  Applicability: Suitable for organic solvent-based stock preparations; do not use in aqueous-only protocols.
  Rationale: Ensures compound can be prepared at high concentrations for dosing in cell culture or animal studies.
  Source Type: Product dossier
• Assay: Storage conditions
  Value: -20°C (solid)
  Applicability: Store powder at -20°C to maintain stability; avoid prolonged storage of solutions.
  Rationale: Mitigates compound degradation and preserves assay reproducibility.
  Source Type: Product dossier
• Assay: Solubility in ethanol
  Value: ≥15.33 mg/mL
  Applicability: Use for ethanol-based stock solutions if DMSO is unsuitable.
  Rationale: Provides alternative solvent compatibility.
  Source Type: Product dossier
• Assay: Purity (QC)
  Value: >96%
  Applicability: Confirm batch quality for experimental reproducibility.
  Rationale: High purity minimizes confounding results from contaminants.
  Source Type: Product dossier

Workflow Setup and QC Checklist

• Stock Preparation: Dissolve BFH772 in DMSO or ethanol to prepare concentrated stocks (e.g., 10–50 mM). Vortex thoroughly and check for full dissolution; do not attempt to dissolve in water due to insolubility (see product details).
• Aliquoting and Storage: Aliquot stocks to minimize freeze-thaw cycles. Store aliquots at -20°C and avoid prolonged storage of solutions, as the compound may degrade more rapidly in solution.
• Quality Control Verification: Confirm batch certificate of analysis and purity (>96%). Review the safety data sheet before handling.
• Assay Controls: Include vehicle controls (DMSO or ethanol at matched concentrations) in all assays to rule out solvent effects.
• Dosing: For in vitro assays, use serial dilutions to achieve target concentrations; for animal studies, consult existing literature for dosing strategies compatible with oral administration and solvent tolerability.

Common Failure Modes and Fixes

• Incomplete dissolution: If BFH772 does not dissolve fully in DMSO or ethanol, ensure the target concentration does not exceed solubility limits. Gentle warming (not above 37°C) and extended vortexing may improve dissolution. Do not use water as a solvent.
• Loss of potency: Avoid repeated freeze-thaw cycles and prolonged storage of BFH772 in solution. Always prepare fresh aliquots for critical experiments and store solids at -20°C.
• Unintended kinase inhibition: While BFH772 is highly selective, verify that your assay system does not require inhibition of kinases other than VEGFR2 (e.g., FLK-1, FLT-1, B-RAF), as potency against these targets is substantially reduced.
• Solvent toxicity: In cell-based and animal assays, ensure the final solvent concentration is well below cytotoxic thresholds. Always run matched vehicle controls.
• Batch inconsistencies: Always confirm batch-specific QC reports and purity before use in critical assays.

Scope and Limitations

BFH772 is intended for research workflows requiring precise inhibition of VEGFR2-mediated angiogenesis, including tumor growth and vascular development studies where kinase selectivity is essential. The compound's >40-fold reduced efficacy against kinases such as B-RAF, RET, and TIE-2, and approximately 500-fold reduced potency against FLK-1, FLT-1, and FLT-4, restricts its utility in experiments requiring broad-spectrum kinase inhibition. It is not compatible with water-based protocols due to insolubility, nor is it suitable for workflows where long-term solution stability is needed. BFH772 should not be used where off-target kinase modulation or water-soluble reagents are required.

Conclusion

BFH772 offers a robust tool for researchers requiring selective inhibition of the VEGFR2 signaling pathway in angiogenesis and tumor biology studies. Its high specificity, clear solubility parameters, and defined storage requirements support reproducible and interpretable results in both in vitro and in vivo models. For complete product specifications, certificates of analysis, and ordering details, refer to BFH772 (VEGFR2 inhibitor) at APExBIO.